Literature DB >> 10363465

Stability of amlodipine besylate in two liquid dosage forms.

M C Nahata1, R S Morosco, T F Hipple.   

Abstract

OBJECTIVE: To determine the stability of amlodipine besylate in two liquid dosage forms under refrigeration and at room temperature.
DESIGN: Commercially available amlodipine tablets (Norvasc-Pfizer) were used to prepare two suspensions: one in extemporaneously prepared 1% methylcellulose in syrup (1:1), and another in equal volumes of commercially available OraPlus/OraSweet. Each suspension containing amlodipine 1 mg/mL was stored in 10 plastic prescription bottles; 5 were stored at 4 degrees C and 5 at 25 degrees C. Samples were collected immediately after preparation (day 0) and on days 7, 14, 28, 42, 56, 70, and 91. Amlodipine concentration was measured by stability-indicating HPLC method (n = 15).
SETTING: Research laboratory at Children's Hospital. MAIN OUTCOME MEASURES: Physical and chemical stability (> 90% of the initial concentration) of amlodipine in the two extemporaneously prepared suspensions during storage in plastic prescription bottles at 4 degrees C and 25 degrees C.
RESULTS: Observed mean concentrations exceeded 90% of the initial concentrations in both suspensions for 91 days at 4 degrees C and 56 days at 25 degrees C. No noticeable change in physical appearance or odor was observed; pH changed slightly in the methylcellulose-containing formulation stored at 25 degrees C.
CONCLUSION: Amlodipine was stable in two suspensions when stored in plastic prescription bottles for 91 days at 4 degrees C or 56 days at 25 degrees C. These formulations may be considered for pediatric or elderly patients who are unable to swallow tablets. The liquid dosage form would also permit accurate administration of amlodipine doses to infants and young children based on their body weight.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10363465     DOI: 10.1016/s1086-5802(16)30454-5

Source DB:  PubMed          Journal:  J Am Pharm Assoc (Wash)        ISSN: 1086-5802


  9 in total

1.  Bioavailability of a pediatric amlodipine suspension.

Authors:  Dorothy A Lyszkiewicz; Zina Levichek; Eran Kozer; Yaron Yagev; Myla Moretti; Marjie Hard; Gideon Koren
Journal:  Pediatr Nephrol       Date:  2003-05-07       Impact factor: 3.714

2.  Stability of Extemporaneously Compounded Amlodipine Besylate Oral Suspensions.

Authors:  Mihaela Friciu; Sarra Zaraa; Grégoire Leclair
Journal:  Can J Hosp Pharm       Date:  2016-08-31

Review 3.  Pharmacologic treatment of chronic pediatric hypertension.

Authors:  Renee F Robinson; Milap C Nahata; Donald L Batisky; John D Mahan
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

4.  Superior palatability of crushed lercanidipine compared with amlodipine among children.

Authors:  Gregorio Milani; Monica Ragazzi; Giacomo D Simonetti; Gian P Ramelli; Mattia Rizzi; Mario G Bianchetti; Emilio F Fossali
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

5.  Efficacy and safety of prolonged amlodipine treatment in hypertensive children.

Authors:  Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2005-03-23       Impact factor: 3.714

Review 6.  A review of calcium channel antagonists in the treatment of pediatric hypertension.

Authors:  Shobha Sahney
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

7.  Systemic Hypertension: Management in Children and Adolescents.

Authors:  Craig W. Belsha
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-08

8.  LC, MS n and LC-MS/MS studies for the characterization of degradation products of amlodipine.

Authors:  Ravi N Tiwari; Nishit Shah; Vikas Bhalani; Anand Mahajan
Journal:  J Pharm Anal       Date:  2014-08-07

Review 9.  Formulations of Amlodipine: A Review.

Authors:  Muhammad Ali Sheraz; Syed Furqan Ahsan; Marium Fatima Khan; Sofia Ahmed; Iqbal Ahmad
Journal:  J Pharm (Cairo)       Date:  2016-10-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.